Relay Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Relay Therapeutics Stock-Based Compensation Growth & History (RLAY)
Relay Therapeutics's stock-based compensation was $62.4M for fiscal 2025.
View full Relay Therapeutics company overviewRelay Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $62.4M | −$31.7M | −33.69% |
| 2024 | 2024-12-31 | $94.1M | $8.1M | +9.42% |
| 2023 | 2023-12-31 | $86.0M | $29.9M | +53.25% |
| 2022 | 2022-12-31 | $56.1M | $7.7M | +15.86% |
| 2021 | 2021-12-31 | $48.5M | $16.5M | +51.61% |
| 2020 | 2020-12-31 | $32.0M | $27.5M | +617.24% |
| 2019 | 2019-12-31 | $4.5M | — | — |
Relay Therapeutics quarterly stock-based compensation
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.2M | −$5.3M | −36.70% |
| Q1 2026 | 2026-03-31 | $10.5M | −$8.8M | −45.47% |
| Q4 2025 | 2025-12-31 | $13.1M | −$4.6M | −25.90% |
| Q3 2025 | 2025-09-30 | $15.5M | −$7.0M | −30.94% |
| Q2 2025 | 2025-06-30 | $14.5M | −$12.3M | −45.96% |
| Q1 2025 | 2025-03-31 | $19.3M | −$7.9M | −28.92% |
| Q4 2024 | 2024-12-31 | $17.6M | −$1.6M | −8.47% |
| Q3 2024 | 2024-09-30 | $22.5M | $649,000 | +2.97% |
| Q2 2024 | 2024-06-30 | $26.8M | $3.4M | +14.61% |
| Q1 2024 | 2024-03-31 | $27.2M | $5.7M | +26.35% |
| Q4 2023 | 2023-12-31 | $19.3M | $5.5M | +39.44% |
| Q3 2023 | 2023-09-30 | $21.8M | $8.1M | +59.16% |
| Q2 2023 | 2023-06-30 | $23.4M | $8.3M | +54.56% |
| Q1 2023 | 2023-03-31 | $21.5M | $8.1M | +59.93% |
| Q4 2022 | 2022-12-31 | $13.8M | $3.6M | +35.22% |
| Q3 2022 | 2022-09-30 | $13.7M | $1.3M | +10.48% |
| Q2 2022 | 2022-06-30 | $15.1M | −$1.0M | −6.19% |
| Q1 2022 | 2022-03-31 | $13.5M | $3.8M | +39.13% |
| Q4 2021 | 2021-12-31 | $10.2M | −$4.3M | −29.74% |
| Q3 2021 | 2021-09-30 | $12.4M | $489,000 | +4.10% |
| Q2 2021 | 2021-06-30 | $16.1M | $12.1M | +300.47% |
| Q1 2021 | 2021-03-31 | $9.7M | $8.2M | +564.67% |
| Q4 2020 | 2020-12-31 | $14.5M | — | — |
| Q3 2020 | 2020-09-30 | $11.9M | $10.7M | +855.85% |
| Q2 2020 | 2020-06-30 | $4.0M | $2.9M | +271.27% |
| Q1 2020 | 2020-03-31 | $1.5M | — | — |
| Q3 2019 | 2019-09-30 | $1.2M | — | — |
| Q2 2019 | 2019-06-30 | $1.1M | — | — |
Relay Therapeutics stock-based compensation trends
Over the last five fiscal years, Relay Therapeutics's stock-based compensation increased from $32.0M to $62.4M, a change of $30.5M. The latest reported quarter, Q2 2026, shows $9.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relay Therapeutics source filings ↗